Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 457

Sort by

Sort Order Select

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Roland Jäger, PhD, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, PhD, Kurt Krejcy, MD, Christoph Klade, PhD, Michael Zoerer, PhD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2019) 134 (Supplement_1): 1685.

https://doi.org/10.1182/blood-2019-130139

Published: 2019

Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Blood (2019) 134 (Supplement_1): 36.

https://doi.org/10.1182/blood-2019-125825

Published: 2019

Journal Articles

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Luis Colomo, Ivonne Vazquez, Natalia Papaleo, Marta Salido, Anna Puiggros, Blanca Espinet, Maria Rodriguez-Rivera, Ramon Diez-Feijoo, Blanca Sanchez-Gonzalez, Antonio Salar, Ana Ferrer, Leonor Arenillas, Marcio Andrade Campos, MD PhD, Xavier Calvo

Blood (2019) 134 (Supplement_1): 2899.

https://doi.org/10.1182/blood-2019-125717

Published: 2019

Journal Articles

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma

Marion Eveillard, Even H Rustad, MD, Mikhail Roshal, MD PhD, Yanming Zhang, MD, Amanda Kathryn Ciardiello, Neha Korde, MD, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Eric L Smith, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 3060.

https://doi.org/10.1182/blood-2019-123838

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Binod Dhakal, MBBS, Muhammad Umair Mushtaq, MD, Ashley Cunningham, MD, Athanasios Papadas, MD, Adam Pagenkopf, BS, Joshua Wiesner, Catherine Leith, MBBChir, Peiman Hematti, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 3088.

https://doi.org/10.1182/blood-2019-127565

Published: 2019

Journal Articles

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Debra Hoppensteadt, PhD, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, MD, Walter Jeske, PhD, Jeanine Walenga, PhD, Alfonso J Tafur, MD MS, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3374.

https://doi.org/10.1182/blood-2019-131221

Published: 2019

Journal Articles

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Aurelie Baudet, PhD, Karolina Paulina Komorowska, PhD, Hultmark Simon, MS, Marcus Järås, PhD, Marion Chapellier, PhD, Gunnar Juliusson, MD PhD, Mattias Magnusson, PhD

Blood (2019) 134 (Supplement_1): 2466.

https://doi.org/10.1182/blood-2019-122661

Published: 2019

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

Journal Articles

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Chung Hoow Kok, PhD BSc, Liu Liu, PhD BSc, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Verity A Saunders, Phuong Dang, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 663.

https://doi.org/10.1182/blood-2019-125446

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Martha Hernandez-Illas, Tong Lin, Andres Rey, Jack Jenkins, Reddy Chandula, Mi Rim Choi, MD

Blood (2019) 134 (Supplement_1): 3817.

https://doi.org/10.1182/blood-2019-123695

Published: 2019

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 1112.

https://doi.org/10.1182/blood-2019-130559

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

A Computational Based Approach for Identification and Validation of Gene Mutations As Surrogate Markers of Gene Essentiality in Acute Myeloid Leukemia

Fernando Carazo, Edurne San Jose, Leire Garate, Estibaliz Miranda, Ana Alfonso Pierola, MD PhD, Sara Villar, Jose J. Rifon Roca, MD, Bruno Paiva, PhD, Jesús San-Miguel, Xabier Agirre, PhD, Felipe Prósper, MD PhD, Angel Rubio

Blood (2019) 134 (Supplement_1): 1414.

https://doi.org/10.1182/blood-2019-126506

Published: 2019

Journal Articles

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Takahiro Kobayashi, MD PhD, Yuki Fujioka, MD PhD, Sho Ikeda, MD PhD, Hiroyoshi Nishikawa, MD PhD, Naoto Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 1792.

https://doi.org/10.1182/blood-2019-125649

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

Higher Rates of Death and Major Bleeding Highlight the Inequities That Exist in the Care of People with Venous Thromboembolism Who Experience Social Exclusion: Findings from a Prospective Registry of 79735 Patients (RIETE)

Karl Ewins, Fionnuala Ni Ainle, PhD, Cliona Ni Cheallaigh, MB BCH MRCPI PhD, Eoghan Dunlea, MB BCh MRCPI, Sarah Kelliher, MBBS, Egidio Imbalzano, MD, Cristiano Bortoluzzi, MD, Inés Jou, MD, Joaquín Alfonso-Megido, María del Carmen Díaz-Pedroche, Manuel Monreal, MD PhD

Blood (2019) 134 (Supplement_1): 4677.

https://doi.org/10.1182/blood-2019-130745

Published: 2019

NARROW

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

A Computational Based Approach for Identification and Validation of Gene Mutations As Surrogate Markers of Gene Essentiality in Acute Myeloid Leukemia

Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Higher Rates of Death and Major Bleeding Highlight the Inequities That Exist in the Care of People with Venous Thromboembolism Who Experience Social Exclusion: Findings from a Prospective Registry of 79735 Patients (RIETE)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only